2/26/2013

Intersect ENT has secured $30 million in a round of Series D financing that again includes Medtronic. The Menlo Park, Calif.-based company will use the proceeds in part to continue to expand U.S. sales of its Propel and Propel mini implants for treating chronic sinusitis.

Related Summaries